The CD19/CD20 Dual-CAR-T therapy is positioned to address a significant unmet medical need in the treatment of refractory and relapsed B-cell leukemia, a condition with limited effective treatment options. The single-arm, open-label design of this Phase 1 trial suggests a focus on early safety and efficacy evaluation, which may facilitate rapid development and potential market entry. Given the increasing interest in CAR-T therapies, particularly in hematological malignancies, successful outcomes could enhance competitive positioning against existing therapies such as Kymriah and Yescarta. The collaboration with China Immunotech (Beijing) Biotechnology Co., Ltd. may provide additional resources and expertise, potentially accelerating development timelines. However, the trial's single-center nature may limit generalizability and raise concerns regarding scalability and manufacturing capabilities.